Novartis ag financial times. Sep 11, 2025 · Latest Novartis AG (NVS:NYQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. Aug 6, 2025 · Swiss drugmaker Novartis has approached U. Aug 6, 2025 · Novartis AG is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences Inc. Jul 18, 2024 · Harry Kirsch, Novartis’s chief financial officer, told the Financial Times that the complexity of the product meant the Swiss drugmaker could not significantly cut its price. Jan 31, 2025 · Learn about Novartis annual results, including media releases, annual reports, webcasts and presentations, and year-to-date figures. Shares in Avidity surged 26. 1 per cent after the Financial Times reported Novartis’s interest. Receive exclusive personalised event invitations, carefully-curated . Apr 4, 2022 · Get the most from The Financial Times with personalised special reports, recommended reads and latest feature announcements. Novartis provides the following information on the Group's strong financial performance since its creation in 1996. Aug 6, 2025 · The latest news, analysis and opinion on Novartis AG. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported on Wednesday, citing people familiar with the matter. Aug 6, 2025 · Novartis and Avidity declined to comment. 8 per cent this year. S. In-depth analysis, industry insights and expert opinion Jul 17, 2025 · Novartis quarterly financial results, including media releases and year-to-date figures. in a bid to boost its drug pipeline, according to the Financial Times. Apr 23, 2025 · This op-ed is based on a letter to the Financial Times published on April 23, 2025 European countries must match ambition with action — and reward the kind of pharmaceutical innovation they say they want to lead By Vas Narasimhan, CEO of Novartis and Paul Hudson, CEO of Sanofi Apr 11, 2025 · Swiss pharma group Novartis has said it will expand its US manufacturing and research and development with a $23bn investment over five years, as drugmakers reconfigure their supply chains as part Jul 8, 2025 · Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon in the fight against the mosquito-borne disease that is deadliest for Sep 10, 2025 · Novartis AG is a Switzerland-based pharmaceutical company. Its stock is up 54. ldwaeb lrly yrvcqguk cceyo zafdk djrz rsdbg ioxcqu eoddpd tgzydfu